The Short Answer
BioMarin stock (BMRN) is doubtful under the current filing-based screen for Muslim investors. BioMarin Pharmaceutical develops and markets therapies for serious and life-threatening rare genetic diseases, including enzyme-replacement therapies, small molecules, and gene therapy. Developing and selling medicines that treat rare diseases is generally permissible, but the current liquidity and receivables screens fail.
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
1,500 / 8,591.016
5,294.87 / 8,591.016
3,126.349 / 8,591.016
22.56 / 766.208
- Financial
- Fails
- Overall
- Fails
Debt/assets is 17.46%, liquidity/assets is 61.63% and receivables plus cash/assets is 36.39%; liquidity/assets is above the examined FTSE limit and interest income/revenue is 2.94%.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 61.63% and receivables plus cash/assets is 36.39%, above the examined MSCI total-assets limits; debt/assets is 17.46% and interest income/revenue is 2.94%.
- Financial
- Fails
- Overall
- Fails
Identifiable liquidity/assets is 61.63%, above the examined Malaysia SAC limit; debt/assets is 17.46%. This is not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; the asset-based screens fail on liquidity and receivables-plus-cash.
Business-activity disclosure
BioMarin develops and markets therapies for rare genetic diseases. Pharmaceutical research and treatment are generally permissible, while product approvals, collaborations and pricing disclosures require continuing review.
Limitation: The filing does not allocate every product, collaboration or pipeline revenue stream into a universal prohibited-activity numerator.
Purification
BioMarin discloses $22.56 million of investment income interest, but no scholar-approved purification percentage is inferred.
Inputs, assumptions and primary sources
- Amounts are USD millions from BioMarin's March 31, 2026 Form 10-Q.
- Debt uses the $1,500 million debt-instrument carrying amount for convertible notes; operating leases are excluded.
- Cash and cash equivalents are $2,222.435 million. Available-for-sale debt securities are $3,072.435 million and are included as identifiable interest-bearing securities; restricted cash is not added again.
- Accounts receivable, net is $903.914 million and first-quarter revenue is $766.208 million.
- Investment income interest is $22.56 million; the filing does not provide a universal prohibited-revenue numerator for every medicine, collaboration or customer end use.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
The verdict depends on the balance sheet: BioMarin has historically used convertible notes and other financing, so confirm the total-debt-to-market-cap ratio against the 33% threshold using the latest filings, and purify the interest income on cash.
Sharia Screening Methodology
Islamic scholars use several criteria to screen stocks:
- Business activity screen: Is the company's primary business halal?
- Debt ratio: Total debt / market cap must be under 33%
- Interest income: Interest income / total revenue must be under 5%
- Haram revenue: Revenue from haram sources must be under 5%
- Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)
What BioMarin Does
BioMarin Pharmaceutical Inc. (headquartered in San Rafael, California) develops and markets therapies for rare genetic diseases:
- Enzyme-replacement therapies: Treatments for rare metabolic disorders.
- Small molecules: Including therapies for skeletal and metabolic conditions.
- Gene therapy: Gene-transfer programs for rare genetic diseases.
Developing and selling medicines that treat rare diseases is a permissible activity, so the business-activity screen passes.
Why It Passes (and What to Check)
1. Permissible Core Business
BioMarin's revenue comes from therapies that treat rare genetic diseases — a clearly permissible activity that benefits human health. There is no haram revenue line.
2. Debt Ratio (Deciding Screen)
BioMarin has historically used convertible notes and other financing, so confirm the total-debt-to-market-cap ratio against the 33% threshold using the latest filings. This is the deciding screen for the verdict.
3. Interest Income (Purify)
BioMarin's March 31, 2026 filing reports $22.56 million of investment income interest, or 2.94% of first-quarter revenue. The corresponding purification treatment depends on the scholar or methodology followed.
Financial Ratios
Based on BioMarin's March 31, 2026 Form 10-Q (USD millions):
- Debt / Assets: 17.46% — below the examined limits ✅
- Liquidity / Assets: 61.63% — above the examined 33.333% limit ❌
- Receivables + Cash / Assets: 36.39% — above the examined MSCI limit ❌
- Investment income interest / Revenue: 2.94% disclosed ✅/⚠️
The current asset-based result fails on liquidity and receivables-plus-cash despite debt/assets passing. Pharmaceutical activity remains generally permissible, but BMRN is doubtful under this screen.
What About Purification?
BioMarin discloses investment income interest, but this page does not infer a scholar-approved purification percentage. The asset-based screen fails independently on liquidity and receivables-plus-cash.
Methodology Interpretation
The current filing-based asset screen fails on liquidity and receivables-plus-cash. Business activity, market-cap denominators, security classification and purification remain methodology-dependent. This is a ZakatInvest analysis, not an official index or agency classification.
Bottom Line
BioMarin (BMRN) is doubtful for Muslim investors under the current filing-based screen. The rare-disease medicine business is generally permissible and debt/assets is 17.46%, but liquidity/assets of 61.63% and receivables-plus-cash/assets of 36.39% exceed the examined limits. Re-screen after the next filing and follow the methodology a reader uses.
Want to check if another stock is halal? Use our free screener.
Open Halal Checker →